Merck & Co Inc <MRK.N>: RBC Cuts to Sector Perform From Outperform; Raises Target Price to $150 From $142
MRK•Related News
Ultragenyx rises after securing FDA nod for rare metabolic disorder gene therapy
RARE•
Walmart Q2 Adjusted EPS USD 0.81 Vs. IBES Estimate USD 0.74
WMT•
Advance Auto Parts Q2 sales miss estimates, hurt by weak DIY demand
AAP•
Campbell's Co <CPB.O>: UBS Raises Target Price to $18 From $17
CPB•
AC Immune reports positive interim Phase 1 data for NLRP3 inhibitor ACI-19764
ACIU•